eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperthermia |
| Comorbidity | C1140680|ovarian cancer |
| Sentences | 6 |
| PubMedID- 21474115 | Background: few data exist on the treatment of peritoneal surface dissemination (psd) from ovarian cancer (oc) with hyperthermic intraperitoneal chemotherapy (hipec). |
| PubMedID- 24675243 | Aim: the present study reports our experience concerning with the advanced cancer treatment (cytoreductive surgery and hyperthermic intraperitoneal chemotherapy) in patients with advanced ovarian cancer ephitelial (aeos) or recurrent ovarian cancer ephitelial (reoc). |
| PubMedID- 26384807 | Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. |
| PubMedID- 20878160 | Txt 75–100 mg/m2 every 3–4 weeks is associated with a quite pronounced neutropenia, with an up to 44% rate of febrile neutropenia in patients with recurrent ovarian cancer [17]. |
| PubMedID- 24657302 | Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. |
| PubMedID- 24761216 | Clinical trials have reported that the incidence of febrile neutropenia in patients with ovarian cancer receiving paclitaxel and carboplatin (tc) chemotherapy is<10% [9,10], and the guidelines indicate that csfs are not needed for primary prophylaxis in these patients. |
Page: 1